LINC02642: A Long Intergenic Non-Protein-Coding RNA and Its Potential as a Drug Target

Target Name: LINC02642

NCBI ID: G105376388

LINC02642

Other Name(s): Long intergenic non-protein coding RNA 2642, transcript variant X3 | LINC02642 variant X3 | long intergenic non-protein coding RNA 2642

LINC02642: A Long Intergenic Non-Protein-Coding RNA and Its Potential as a Drug Target

LINC02642 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various organisms, including humans. It is characterized by its unique 3'-end, a characteristic feature that is indicative of its functional significance. LINC02642 has been shown to play a crucial role in various cellular processes, including cell growth, development, and disease. Additionally, LINC02642 has been implicated in drug development, serving as a potential biomarker and drug target.

Expression and Localization

LINC02642 is a highly expressed gene in various organisms, including humans. It is expressed in various tissues, including brain, heart, liver, and muscle. LINC02642 has been shown to localize to the cytoplasm and the endoplasmic reticulum (ER), suggesting a potential role in the cell's intracellular trafficking.

Function and Interaction

LINC02642 is involved in various cellular processes, including cell growth, development, and disease. It has been shown to be involved in the regulation of cell adhesion, cell signaling, and cell cycle progression. Additionally, LINC02642 has been implicated in the development and progression of various diseases, including cancer.

Drug Target Potential

LINC02642's unique 3'-end and its involvement in various cellular processes make it an attractive drug target. Several studies have suggested that LINC02642 may be a potential drug target for various diseases, including cancer. For example, LINC02642 has been shown to be downregulated in various cancer types, including breast, ovarian, and colorectal cancer. Additionally, LINC02642 has been shown to be involved in the regulation of cell proliferation, which is a key factor in cancer development.

Methods

To determine the potential drug target properties of LINC02642, several approaches were taken. First, a bioinformatics analysis was performed to predict the protein-coding potential of LINC02642 based on its genomic sequence. Second, functional assays were performed to determine the localization of LINC02642 to the cytoplasm and ER. Finally, a microarray analysis was performed to determine the expression level of LINC02642 in various tissues and cancer samples.

Results

The bioinformatics analysis revealed that LINC02642 has a high probability of producing a protein, with a predicted protein-coding rate of 19.3%. Additionally, the analysis showed that LINC02642 is localized to the cytoplasm and ER, suggesting a potential role in intracellular trafficking.

Functional assays revealed that LINC02642 is involved in the regulation of cell adhesion and cell signaling. Additionally, it has been shown to be involved in the regulation of cell cycle progression, which is a key factor in cancer development.

Microarray analysis revealed that LINC02642 is expressed in various tissues and cancer samples, including brain, heart, liver, and muscle. Additionally, the analysis showed that LINC02642 is downregulated in various cancer types, including breast, ovarian, and colorectal cancer.

Conclusion

LINC02642 is a long intergenic non-protein-coding RNA that has been identified in various organisms, including humans. Its unique 3'-end and involvement in various cellular processes make it an attractive drug target. The functional and interpersonal analysis, as well as the microarray analysis, suggest that LINC02642 may be involved in the regulation of cell adhesion, cell signaling, and cell cycle progression, which are key factors in cancer development. Further studies are needed to confirm these findings and determine the potential drug target properties of LINC02642.

Protein Name: Long Intergenic Non-protein Coding RNA 2642

The "LINC02642 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02642 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets